|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
JE Karp, PJ Burke and RL Humphrey
Sequential sera from 45 patients with multiple myeloma (MM) and from 6
patients with solid tumors but normal bone marrows who received
cyclophosphamide, 15 mg/kg/day for 4 days, were assayed for their effects
on tritiated thymidine (3H-TdR) incorporation by normal bone marrow cells
and malignant plasma cells. Pretreatment sera from 23 of the 45 patients
with MM inhibited normal marrow cell proliferation relative to the effects
of normal sera. Of these 45 sera, 30 inhibited plasma cell proliferation.
This humoral inhibition was overcome by the induction of humoral
stimulation at a predictable time during chemotherapy. The sera obtained
sequentially from patients with MM and patients with normal bone marrows
increased 3H-TdR uptake by both cell types by days 12-15 of therapy.
Sequential changes in malignant marrow plasma cell 3H-TdR labeling indices
paralleled the changes in serum activity, with an increased tumor cell
growth fraction occurring at the time of peak serum stimulatory activity.
The relationship between serum stimulation and malignant plasma cell
proliferation was confirmed in vitro.
|
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 1977 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
